Baylor University technology helps Acer Therapeutics raise $2.1m in funding to help those affected by Maple Syrup Urine Disease.
Acer Therapeutics, a US-based biotechnology company using technology licensed from Baylor University, has raised $2.1m.
The company is developing new treatments by using existing therapies and repurposing and reformulating them in order to treat a rare condition called Maple Syrup Urine Disease, also known as branched-chain ketoaciduria.
Acer Therapeutics, through Baylor University, currently has a phase 3 clinical trial running. The only current treatment of the disease is dietary changes and close monitoring of blood levels.
Affecting around 4000 people in the world, the disease is caused by a metabolic disorder. Over time branched-chain amino acids and their by-products build up in the blood and urine and if left untreated can cause brain damage and death.
